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Lipopheresis in the nephrotic syndrome. tients, multiple pharmacotherapy, and the presence of
Background. Experimental models have established a role other risk factors such as hypertension and significant
for lipoproteins in the pathogenesis of progressive renal failure. nephron loss.However, conventional treatment rarely normalizes the high
Because of the paucity of information on the use ofserum cholesterol of the nephrotic syndrome. The removal of
lipopheresis in nephrotics, we used extracorporeal low-low-density lipoprotein by lipopheresis is discussed.
Methods. Lipopheresis may be beneficial in nephrotic pa- density lipoprotein (LDL) apheresis to achieve reduc-
tients with focal segmental glomerulosclerosis. The authors tions in LDL of 60 to 70% in an 18-month controlled
studied the long-term effects of low-density lipoprotein choles- trial. LDL apheresis has been safely used in familialterol (LDL-C) removal using the Kaneka Liposorber system,
hypercholesterolemia [4], coronary artery disease heartwhich binds LDL-C to dextran sulfate in a controlled trial in
disease [5], and peripheral vascular disease [6]. In ne-20 nephrotic patients with different renal diseases.
Results. A 21-month clamp of plasma total cholesterol at phrotics with steroid-resistant focal segmental glomeru-
6.0 mmol/liter or below was significantly lower than controls losclerosis, there were short-term improvements in se-
(x2 5 84.3, P , 0.001), followed 12 aphereses over 6 to 12 rum albumin, proteinuria, and creatinine clearance (CCr)weeks in all but three apheresed patients. 1/Cr slopes were
in over 50% of those treated in several uncontrolledunchanged when the 50-day average period of lipopheresis
trials (Table 1) [7, 8]. Additional case reports also sug-treatments was excluded from analysis. Proteinuria was not
reduced, but serum albumin tended to rise (NS). Fibrinogen gested that LDL apheresis was clinically valuable [7–9].
fell by 29.8%; high-density lipoprotein, apoA1, and Lp(a) were
unchanged. Two apheresed patients had a prolonged remission
with a reduction of proteinuria to less than 250 mg/24 hr. The METHODS
reasons for prolonged reduction of total cholesterol include
Patientsdepletion of tissue cholesterol, an improved fractional catabolic
rate of very low density lipoprotein (VLDL), increased hepato- Twenty nephrotic patients with a variety of biopsy-
cyte LDL turnover, and the maintenance of statin therapy. proven glomerular diseases causing persistent hyperlip-Conclusion. Lipopheresis is a safe and effective method for
idemia and proteinuria were allocated to two groups bythe control of LDL in nephrotic syndrome. Early clamping of
the minimization technique after informed consent. Alltotal cholesterol in the normal range resulted in a prolonged
and significant reduction of LDL compared with controls. had persistent proteinuria of more than 1.2 g/24 hr, and
a CCr of more than 18 ml/min. Patients with amyloidosis,
diabetes, endocrine or hepatic disease, minimal change
The relationship between lipoproteins and renal dis- disease, and/or a renal transplant were excluded.
ease has been summarized in numerous publications
Randomization[1, 2] and conclusively demonstrated in animal experi-
ments. Experimental evidence suggests that lipid-induced Patients were allocated to lipopheresis treatment (group
glomerular lesions have a pathogenesis analogous to ath- A) or drugs (group B) in such a way as to minimize
erosclerosis and that the lesions can be prevented or the difference in scores between the groups, using five
ameliorated by lipid-lowering therapy [1, 3]. In humans, prognostic factors: proteinuria of more than 3.0 g/24 hr,
however, the results of therapy using equivalent lipid- age of more than 45 years, male gender, glomerular fil-
lowering regimes have been disappointing, although this tration rate (GFR) of less than 65 ml/min, and concurrent
approach has not been fully tested in nephrotic patients. immunosuppression. Group A had 11 patients, and group
The reasons cited for this include small trials, the relative B had 9 patients.
ineffectiveness of lipid-lowering therapy in nephrotic pa-
Apheresis group
In group A, lipopheresis of 2.5 to 4.0 liters of plasmaKey words: apheresis, statin, proteinuria, fibrinogen, cholesterol clamp,
lipoprotein. was performed 12 times over 6 to 12 weeks, and total
cholesterol was clamped at 6.0 mmol/liter or less using 1999 by the International Society of Nephrology
S-6
Brunton et al: Lipopheresis in the nephrotic syndrome S-7
Table 1. Lipopheresis in two uncontrolled trials [7, 8]
Reference N of Creatinine Clinical
author patients Proteinuria clearance notes
[7] Sakai et al 16 Down by 84% Up in 16 Useful in 56%
[8] Muso et al 8 Down 50% in 3 Up in 7 Steroid
No change in 5 resistant
FSGS
the Kaneka Liposorber. LDL apheresis was followed
by the administration of an 3-hydroxy-3-methylglutaryl
co-enzyme A (HMG-CoA) reductase inhibitor (simva-
statin) to maintain a significant and sustained reduction
in serum total cholesterol, LDL cholesterol (Fig. 1), and
triglyceride for a period of up to 18 months.
Drugs group
Group B patients were treated with drugs alone. Sim-
vastatin at 40 mg/day was given to both groups.
RESULTS
Group A
Low-density lipoprotein cholesterol (LDL-C) was #/5
4.0 mmol/liter for 113 months in apheresed patients ver-
sus only 19 months for drugs alone. In group A, the
LDL-C was .4.0 mmol/liter for 74 months vs. 138
months for drugs alone (x2 5 84.3, P , 0.001). Serum
apoB levels mirrored the reduction in LDL, whereas
high-density lipoprotein cholesterol levels, apolipoprot-
ein A1, and lipoprotein(a) [Lp(a)] remained unchanged.
In Group A, the total cholesterol was clamped at or Fig. 1. Prolonged reduction in low-density lipoprotein (LDL) choles-
terol in the lipopheresis group by comparison with the drugs group.below 6.0 mmol/liter from a mean start level of 9.92
(A) Total cholesterol in the lipopheresis group. (B) Total cholesterolmmol/liter. Fibrinogen fell by 29.8% (P , 0.01) com- in the drugs group.
pared with preapheresis levels, and there was an upward
but nonsignificant trend in serum albumin. Interestingly,
two apheresis patients had a sustained remission with
patients. Interestingly, serum cholesterol control ex-urine protein concentrations of less than 250 mg/liter
tended far beyond the 50-day mean duration of apher-and a rise in serum albumin to more than 40 g/liter.
esis. In addition, the remission in two participants, oneBecause apheresis treatments lasted 50 days on average
male and one female, both aged 70 years, with membra-to complete, this treatment period was excluded from
nous and mesangiocapillary glomerulonephritis, respec-analysis of changes in renal function. When analyzed
tively, occurred despite previous unresponsiveness tothis way, there was no demonstrable difference between
immunosuppressive drugs. Their age, nephrotic rangegroups in urinary protein excretion, rate of progression
proteinuria, and diagnoses put them in a poor prognosticof renal disease using 1/Cr plots, rate of change of GFR
group, and they both had extensive glomerular basementin ml/min/month, percentage change in GFR, change in
membrane apoE deposition in renal biopsies. Althougheffective renal plasma flow, or change in filtration frac-
there was no effect on proteinuria or progression oftion. The blood pressure was unaffected.
disease in the majority, all of the patients continue to
be followed because many cardiovascular studies suggest
DISCUSSION that the benefit of lipid lowering cannot be clearly estab-
lished until between two and five years after the treat-The technique demonstrated, to our knowledge for
the first time, that the cholesterol level could be effec- ment has been started [10].
The mechanism by which the “cholesterol clamp” wastively and safely clamped at the arbitrarily chosen level
of 6.0 mmol/liter or below in hyperlipidemic nephrotic achieved can only be speculated upon, as the processes
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involved in nephrotic hyperlipidemia are incompletely concentrations of oleate-saturated albumin inhibit apoB
degradation and high free fatty acid (FFA) concentra-understood. However, the reduction of plasma LDL lev-
els by up to 70% probably up-regulates LDL receptors, tions inhibit LPL activity. In addition, increased chylomi-
cron remnants have been shown to stimulate apoB secre-whereas the up-regulation of HMG-CoA reductase is
prevented by the coadministration of a statin. Simva- tion threefold in HepG2 cells, an effect that is even more
statin, the most potent HMG-CoA reductase inhibitor pronounced when the albumin concentration is low [17].
available at the time of the study, was given at a dose The trend toward an increase in serum albumin and
of 40 mg/day. It is likely that aggressive reduction of possibly postapheresis changes in lipoprotein and fatty
plasma cholesterol led to both mobilization of tissue acid composition may have redressed the balance in fa-
stores of cholesterol [11] and constitutive release of apoB vor of intracellular degradation of apoB and an improved
lipoprotein from the liver [12]. Twice-weekly treatments lipoprotein FCR. The kidney’s high oxygen consumption
may have depleted these stores, leading to a resetting depends on a high renal blood flow, and there were
of the steady state at a significantly lower level. The short-term postapheresis improvements in effective re-
significant improvement in triglyceride in apheresed pa- nal plasma flow that were not sustained when studied at
tients would suggest an improved fractional catabolic six month intervals. Comparable studies of apheresis in
rate (FCR) of very low density lipoprotein (VLDL), cardiovascular and familial hypercholesterolemia (FH)
which would also be reflected in lower plasma LDL. In patients have shown significant improvements in renal
addition, we suggest that the cholesterol ester-rich plasma flow following a single treatment [18]. It is there-
VLDL synthesized in the nephrotic syndrome is a less fore possible that temporary reductions occurred in cir-
favored substrate of LPL and is less easily metabolized culating mevalonate, which is oxidized in the kidney to
than the triglyceride-rich VLDL that replaces it after form sterols, nonsterols and carbon dioxide.
lipopheresis. The resulting improvement in FCR and A cholesterol “clamp” was not achieved in three li-
lower VLDL has been shown to improve the apo-CIII popheresis patients. Although no specific apoE genotype
fraction and thus shift the ratio of CII/CIII such that was present in these three, one had an E3/E2 phenotype
LPL activity is increased [13]. This may have occurred that unmasked a type III dysbetalipoproteinemia in the
in our current study. presence of renal disease. He nevertheless achieved a
At the beginning of a course of apheresis, total plasma 70% reduction in triglyceride and a 57% reduction in
cholesterol rose to pretreatment levels within two to total cholesterol. The other two patients had no unre-
four days, but as apheresis treatments incremented, the markable clinical features, but all three had heavy pro-
starting concentration of cholesterol was much lower teinuria, and it is possible that they had excessive urinary
than at the beginning of treatment. Cholesterol synthesis loss of an 39-59-adenosine monophosphate (AMP)-acti-
was probably supplemented by cholesterol mobilization vated protein kinase that inactivates HMG-CoA reduc-
from tissues or constitutive hepatic release of apoB with tase and acetyl-coA carboxylase, the rate-limiting en-
VLDL secretion. There was no significant reduction in zyme of fatty acid synthesis [19].
proteinuria during the study. Renal clearance of albumin The observed increase noted in serum albumin with-
has been shown by Davies et al [14] and Kaysen et al out a concomitant reduction in net urine protein loss
[15] to be the major stimulus for lipid synthesis. Except in underlines the poor correlation between these two vari-
those who remitted, only mild reductions in proteinuria ables, as previously noted in progressive renal failure
were noted during the twice-weekly apheresis treatment patients whose urinary protein excretion did not change
period. It is possible that this change, however small, [20]. Urine protein excretion is the net loss of filtered
may have been sufficient to reduce the “proteinuria stim- protein after tubular reabsorption; it does not need to
ulus” to LDL secretion allowing the latter to be re- be altered by lipid-lowering strategies and is a poor guide
established at a lower rate. LDL apheresis may have to their efficacy. Its contribution will always remain un-
removed or altered the flux of other contributors to hy- known in the absence of the ability to measure the two
percholesterolemia. Receptor associated protein (RAP) unquantifiable major variables of filtered and reabsorbed
and a2-macroglobulin are two candidate proteins that protein.
may have been present in increased concentrations fol-
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is regulated by RAP and responsible for removal of apoE
containing lipoprotein [16], namely VLDL remnants and REFERENCES
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